Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and clustering of cardiovascular risk factors in a population aged 25-64 in Czechia: A cross-sectional study.

PloS one·2025
Same author

Type 2 Diabetes Health Care Outcomes for Patients with Alcohol Use Disorder Starting Addiction Treatment.

Journal of general internal medicine·2025
Same author

Association of depressive symptoms and social determinants of health in medical students of four countries - Czechia, Iran, Kenya, and Venezuela.

Central European journal of public health·2025
Same author

Neonatal hypoglycaemia in the offsprings of parents with maturity-onset diabetes of the young (MODY).

Journal of pediatric endocrinology & metabolism : JPEM·2025
Same author

Prevalence of smoking and smoking cessation and associated factors in diabetes population aged 50 years and over in Europe.

Scientific reports·2025
Same author

Hypertension in Czech Adults Aged 25-64: Prevalence, Awareness, Control, and Risk Factors in 2019 - A Cross-Sectional Study.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre·2025
Same journal

Foot mycoses - treatment with over-the-counter preparations based on clinical recommendations.

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti·2026
Same journal

Travel first aid kit 2026.

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti·2026
Same journal

Atrasentan: new molecule in the therapy of IgA nephropathy and other glomerulopathies.

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti·2026
Same journal

Pulmonary delivery of monoclonal antibodies: challenges, limitations,and modern formulation strategies.

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti·2026
Same journal

Pharmaceutical care in self-medication: ABC/VED analysis of over-the-counter antiallergic medicines.

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti·2026
Same journal

Justification of a medicinal form development based on the api dimethylammonium 3-methyl-2-(2-((e)-styryl)quinazolin-4-ylthio)butanoate with hepatoprotective and antioxidant effects for the needs of military medicine.

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Tirzepatide.

Jan Brož, Marika Koželuhová, Juraj Michalec

    Ceska a Slovenska Farmacie : Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti
    |June 23, 2026
    PubMed
    Summary
    This summary is machine-generated.

    Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves glycemic control and promotes weight loss in type 2 diabetes and obesity. Its efficacy is dose-dependent, with manageable gastrointestinal side effects.

    Keywords:
    obesitytirzepatidetreatmenttype 2 diabetestype 2 diabetes

    Related Experiment Videos

    Last Updated: Jun 25, 2026

    Multidisciplinary Approach to Obesity Management: A Case Report
    05:10

    Multidisciplinary Approach to Obesity Management: A Case Report

    Published on: May 30, 2025

    Area of Science:

    • Endocrinology
    • Metabolic Diseases
    • Pharmacology

    Background:

    • Type 2 diabetes mellitus (T2DM) and obesity are significant global health challenges.
    • Current treatments have limitations in efficacy and patient adherence.
    • The development of novel therapeutic agents targeting multiple pathways is crucial.

    Purpose of the Study:

    • To evaluate the efficacy and safety of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
    • To analyze the impact of tirzepatide on glycemic control, body weight, and cardiovascular risk factors.
    • To understand the mechanism of action and safety profile of tirzepatide in clinical practice.

    Main Methods:

    • Analysis of available clinical trial data for tirzepatide.
    • Assessment of HbA1c reduction, weight loss percentages, and changes in lipid profiles and inflammatory biomarkers.
    • Evaluation of the incidence and nature of adverse events, particularly gastrointestinal side effects.

    Main Results:

    • Tirzepatide demonstrated significant dose- and duration-dependent reductions in HbA1c (20.4-28.2 mmol/mol).
    • Weight reduction ranged from 5-20.9% over 72 weeks, also dose-dependently.
    • Beneficial effects were observed on cardiovascular risk factors and inflammatory markers.
    • Gastrointestinal side effects were the primary adverse events, leading to discontinuation in 4-10% of patients.

    Conclusions:

    • Tirzepatide is a highly effective therapeutic option for T2DM and obesity.
    • Its dual GIP/GLP-1 receptor agonism offers a novel mechanism for metabolic control.
    • Gradual dose escalation and individualized treatment are key to optimizing outcomes and managing side effects.